Formulation of Pletaal
Cilostazol
Composition Each tablet of PLETAAL Tablets 50 mg contains 50 mg of cilostazol and the following inactive ingredients: microcrystalline cellulose, corn starch, carboxymethyl cellulose calcium, hydroxypropyl methyl cellulose 2910, and magnesium stearate.
Each tablet of PLETAAL Tablets 100 mg contains 100 mg of cilostazol and the following inactive ingredients: microcrystalline cellulose, corn starch, carboxymethyl cellulose calcium, hydroxypropyl methyl cellulose 2910, and magnesium stearate.
Drug class
Antiplatelet, Agents, Hematologic.
Cilostazol is a vasodilator that works by relaxing the muscles in your blood vessels to help them dilate (widen). Cilostazol dilates arteries that supply blood to your legs. Cilostazol also improves circulation by keeping platelets in the blood from sticking together and clotting.
Cilostazol is used to treat the symptoms of intermittent claudication. This condition causes reduced blood flow to the legs, leading to pain while walking. Cilostazol improves your ability to walk longer distances without pain.
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
- Chest pain, pounding heartbeats or fluttering in your chest.
- A light-headed feeling, like you might pass out.
- Fever, chills, sore throat, mouth sores.
- Easy bruising, unusual bleeding, purple or red spots under your skin.
Before taking this medicine
You should not take cilostazol if you have heart failure of any kind. Cilostazol can make this condition worse.
Tell your doctor if you have ever had:
- Bleeding problems
- Liver or kidney disease
- A heart attack orstroke
- If you smoke
Dosge and administration
The recommended dosage of Pletaal is 100 mg b.i.d. taken at least half an hour before or two hours after breakfast and dinner. A dose of 50 mg b.i.d. should be considered during coadministration of such inhibitors of CYP3A4 as ketoconazole, itraconazole, erythromycin and diltiazem, and during coadministration of such inhibitors of CYP2C19 as omeprazole. Patients may respond as early as 2 to 4 weeks after the initiation of therapy, but treatment for up to 12 weeks may be needed before a beneficial effect is experienced.